KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income (2020 - 2025)

Recursion Pharmaceuticals' Net Income history spans 6 years, with the latest figure at -$108.1 million for Q4 2025.

  • For Q4 2025, Net Income rose 39.56% year-over-year to -$108.1 million; the TTM value through Dec 2025 reached -$644.8 million, down 39.06%, while the annual FY2025 figure was -$644.8 million, 39.06% down from the prior year.
  • Net Income reached -$108.1 million in Q4 2025 per RXRX's latest filing, up from -$162.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$30.5 million in Q1 2021 to a low of -$202.5 million in Q1 2025.
  • Average Net Income over 5 years is -$93.2 million, with a median of -$84.0 million recorded in 2023.
  • Peak YoY movement for Net Income: tumbled 153.94% in 2021, then soared 39.56% in 2025.
  • A 5-year view of Net Income shows it stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then tumbled by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Net Income are -$108.1 million (Q4 2025), -$162.3 million (Q3 2025), and -$171.9 million (Q2 2025).